Dr Sophie Legge

2020

• Legge, S.et al. 2020. Clinical indicators of treatment-resistant psychosis. British Journal of Psychiatry 216(5), pp. 259-266. (10.1192/bjp.2019.120)
• Richards, A.et al. 2020. The relationship between polygenic risk scores and cognition in schizophrenia. Schizophrenia Bulletin 46(2), pp. -. (10.1093/schbul/sbz061)
• Dennison, C. A.et al. 2020. Genome-wide association studies in schizophrenia: Recent advances, challenges and future perspective. Schizophrenia Research 217, pp. 4-12. (10.1016/j.schres.2019.10.048)
• Rees, E.et al. 2020. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. Nature Neuroscience 23(2), pp. 179-184. (10.1038/s41593-019-0565-2)
• Kendall, K. M.et al. 2020. Impact of schizophrenia genetic liability on the association between schizophrenia and physical illness: a data linkage study. Bjpsych Open
• Caseras, X.et al. 2020. Effects of genomic copy number variants penetrant for schizophrenia on cortical thickness and surface area in healthy participants from the UK Biobank. British Journal of Psychiatry

2019

• Legge, S.et al. 2019. Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits. JAMA Psychiatry 76(12), pp. 1256-1265. (10.1001/jamapsychiatry.2019.2508)
• Pardinas, A. F.et al. 2019. Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism. American Journal of Psychiatry 176(6), pp. 477-486. (10.1176/appi.ajp.2019.18050589)
• Kendall, K. M.et al. 2019. Association of rare copy number variants with risk of depression. JAMA Psychiatry 76(8), pp. 818-825. (10.1001/jamapsychiatry.2019.0566)
• Legge, S. E.et al. 2019. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Molecular Psychiatry 24, pp. 328-337. (10.1038/s41380-018-0335-7)
• Legge, S. E. and Walters, J. T. 2019. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics 20(4), pp. 279-290. (10.2217/pgs-2018-0188)

2018

• Ruderfer, D. M.et al. 2018. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173(7), pp. 1705-1715., article number: e16. (10.1016/j.cell.2018.05.046)
• Lynham, A.et al. 2018. Examining cognition across the bipolar / schizophrenia diagnostic spectrum. Journal of Psychiatry and Neuroscience 43(3), article number: 170076. (10.1503/jpn.170076)
• Pardinas, A. F.et al. 2018. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nature Genetics 50, pp. 381-389. (10.1038/s41588-018-0059-2)

2017

• Legge, S. E.et al. 2017. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry 22, pp. 1502-1508. (10.1038/mp.2016.97)
• Köhler-Forsberg, O.et al. 2017. Predictors of nonhospitalization and functional response in clozapine treatment: a nationwide, population-based cohort study. Journal of Clinical Psychopharmacology 37(2), pp. 148-154. (10.1097/JCP.0000000000000649)
• McLaughlin, R. L.et al. 2017. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications 8, article number: 14774. (10.1038/ncomms14774)
• Marshall, C. R.et al. 2017. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics 49, pp. 27-35. (10.1038/ng.3725)

2016

• Rees, E.et al. 2016. Analysis of intellectual disability copy number variants for association with schizophrenia. JAMA Psychiatry 73(9), pp. 963-969. (10.1001/jamapsychiatry.2016.1831)
• Pardinas, A.et al. 2016. Common schizophrenia alleles are enriched in mutation-intolerant genes and maintained by background selection. bioRxiv, pp. -. (10.1101/068593)
• Legge, S.et al. 2016. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophrenia Research 174, pp. 113-119. (10.1016/j.schres.2016.05.002)
• Thompson, J. V.et al. 2016. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. Journal of Psychopharmacology 30(5), pp. 436-443. (10.1177/0269881116632376)
• Franke, B.et al. 2016. Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nature Neuroscience 19(3), pp. 420-431. (10.1038/nn.4228)

2015

• Legge, S. E. 2015. Examining treatment response and adverse effects of clozapine. PhD Thesis, Cardiff Univeristy.

2014

• Gusev, A.et al. 2014. Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. American Journal of Human Genetics 95(5), pp. 535-552. (10.1016/j.ajhg.2014.10.004)
• Ripke, S.et al. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510), pp. 421-427. (10.1038/nature13595)
• Rees, E.et al. 2014. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Human Molecular Genetics 23(6), pp. 1669-1676. (10.1093/hmg/ddt540)
• Rees, E.et al. 2014. Analysis of copy number variations at 15 schizophrenia-associated loci. British Journal of Psychiatry 204(2), pp. 108-114. (10.1192/bjp.bp.113.131052)

2013

• Rees, E.et al. 2013. Evidence that duplications of 22q11.2 protect against schizophrenia. Molecular Psychiatry n/a (10.1038/mp.2013.156)
• Kirov, G.et al. 2013. The penetrance of copy number variations for schizophrenia and developmental delay. Biological Psychiatry 75(5), pp. 378-385. (10.1016/j.biopsych.2013.07.022)

2012

• Potter, R.et al. 2012. Missed opportunities: mental disorder in children of parents with depression. British Journal of General Practice (BJGP) 62(600), pp. e487-e493. (10.3399/bjgp12X652355)